New Delhi: Drug major Pfizer is currently in talks with the Indian Government to seek an “expedited approval pathway” for its Covid-19 vaccine.
Pfizer said that there was no concern over the safety of its COVID-19 vaccine, as India insists on small local trials for foreign shots despite a record surge in infections and shortage of doses.
“Pfizer is aware that access to vaccines is critical to ending this pandemic. Unfortunately, our vaccine is not registered in India although our application was submitted months ago. We are currently discussing with the Indian government an expedited approval pathway to make our Pfizer-BioNTech vaccine available for use in the country,” the company’s chairman and CEO Albert Bourla wrote to Pfizer’s India employees in a letter.
The pharmaceutical company had earlier said that it had decided to prioritise orders from the government, and supply doses of its Covid-19 vaccine “only through government contracts” in India.